A Phase 1 interventional study of FZ-AD004 in Advanced and Metastatic Solid Tumor, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 486 studies in Neoplasm Metastasis with a site in China — 223 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.
Among the 486 studies in Neoplasm Metastasis with a site in China, this one is the 168th largest by planned enrollment of the 402 interventional ones that give a count, is one of 41 that started in 2023, is one of 93 in phase 1, reaches primary completion later than 101 of the 262 other live ones, and was the 282nd registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.
Browse Neoplasm Metastasis studies →223 of the 486 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–75
Nanjing Medical University · Sites in China
Ages 18–80
Genovn Therapeutics (Suzhou) Co., Ltd. · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18–75
Taizhou Mabtech Pharmaceutical Co.,Ltd · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
486 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 170 · Phase 3 85 · Phase 4 13
First in 2003; this study’s year is marked. 41 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 121 is above the median of 50 across 3,275 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 90 across the 402 interventional studies, 180 across the 83 observational. Of the 104 that completed or were terminated, 27 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 486 have an industry lead sponsor. The 10 most frequent:
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is the lead sponsor of 25 studies on the registry; 6 are open to participants now.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has 1 study filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
81 of the studies in Neoplasm Metastasis with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT05794971Phase 3Sun Yat-sen UniversityRegorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases | 2027-03-31 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06961188Phase 3Changchun GeneScience Pharmaceutical Co., Ltd.Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis | 2027-06-30 |
Add all 81 to your calendar (.ics) → With an account.
Among the 486 studies in Neoplasm Metastasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.
This is a first-in-human (FIH), Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of FZ-AD004 in patients with advanced/metastatic solid tumors. FZ-AD004 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD) and dose-limiting toxicities(DLT)during cycle 1. In addition, the maximum-tolerated dose and recommended Phase II dose for FZ-AD004 will be determined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled in the dose escalation part or dose expansion part
Drug: FZ-AD004
Dose Escalation:Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study. Dose Expansion:Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles.
Also known as: FZ-AD004-Antibody-drug Conjugate
The dose limiting toxicity ( DLT)
To determine the dose limiting toxicities (DLTs) of FZ-AD004.
Time frame: 21 Days (first cycle)
Maximum Tolerable Dose (MTD)
To determine the maximum tolerated dose (MTD) and/or recommended doses for expansion (RDEs). RDEs will not exceed MTD.
Time frame: 21 Days (first cycle)
Adverse Events
To check the numbers of AEs happened during the course of trial.
Time frame: Screening up to study completion
Objective Response Rate (ORR) according to RECIST 1.1
To evaluate the objective response rate (ORR) \[Complete Response (CR) + Partial Response (PR)\] of FZ-AD004 when administered intravenously (IV) as monotherapy at the RDEs to patients with metastatic or locally advanced unresectable tumors.
Time frame: From subject randomization up to 60 months.
Progression free survival(PFS) according to RECIST 1.1
Progression-free survival (PFS) was defined as the interval from the first dose start date to the date of disease progression defined as documented progressive disease (PD) or death from any cause, whichever occurs first.
Time frame: From subject randomization up to 60 months.
Duration of Response(DOR) according to RECIST 1.1
Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
Time frame: From subject randomization up to 60 months
Overall Survival (OS) according to RECIST 1.1
Overall survival was defined as the time from the date of the first dose start date to the date of death due to any cause.
Time frame: From subject randomization up to 60 months.
Terminal elimination half-life (t1/2) of Total Antibody, Free DXd and FZ-AD004
To check how much time Total Antibody, Free DXd and FZ-AD004 will take to eliminate half of it's concentration from participants.
Time frame: Up to 17 weeks
Maximum observed plasma concentration (Cmax) of Total Antibody, Free DXd and FZ-AD004
o check what will be the maximum concentration participants will obtained of Total Antibody, Free DXd and FZ-AD004 in their blood plasma.
Time frame: Up to 17 weeks
Area under the concentration-time curve (AUC 0-∞) from time 0 to infinity of Total Antibody, Free DXd and FZ-AD004
To check the drug profile for absorption, distribution, metabolism and excretion for Total Antibody, Free DXd and FZ-AD004 in participants blood plasma
Time frame: Up to 17 weeks
Time to Cmax (Tmax) of Total Antibody, Free DXd and FZ-AD004
To check what time will it take to reach the maximum contraction of Total Antibody, Free DXd and FZ-AD004 in study participants
Time frame: Up to 17 weeks
Number of subjects who develop detectable anti-drug antibodies (ADAs)
To check the" Anti Drug Antibody" develops in participants against the FZ-AD004 through blood sample
Time frame: From subject randomization up to 60 months.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 42 months is below that.
Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. →